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Breast MRIAbstract Purpose: To evaluate the role of diffusion weighted imaging and dynamic contrast
enhanced magnetic resonance imaging in characterization of breast tumors and comparing the
results with the histological ﬁnding.
Patients and methods: From January 2011 to January 2015, 71 patients with 74 suspicious breast
lesions had performed breast DCE-MRI combined with DWI and the results were compared with
the histopathological examination which was used as the standard diagnostic method.
Results: The study included 71 patients with 74 suspicious breast lesions, there were 38 benign
lesions ((51.35%) and 36 malignant lesions (48.65%)).
DCE-MRI proved to have a sensitivity of 91.7%, and a speciﬁcity of 84.2%. ADC cutoff value to
differentiate between benign and malignant lesions was 1.32 · 103 mm2/s (P< 0.001). The diffusion
weighted MRI proved to have a sensitivity of 94.4%, and a speciﬁcity of 92.1%.
The combined MRI protocol of DCEMRI and DWI proved to increase the sensitivity and speci-
ﬁcity of breast MRI.(N.A.E.
792 M.A.H. El Bakry et al.Conclusion: DWI had a higher sensitivity and speciﬁcity than DCE-MRI. The combined MRI pro-
tocol of DCEMRI and DWI proved to increase sensitivity and speciﬁcity of MRI in diagnosis and
differential diagnosis of breast lesions.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is the commonest female cancer. It is the 2nd
leading cause of death among female after lung cancer (1).
Improvements in diagnosis of breast cancer are largely respon-
sible for increasing rate of survival among breast cancer
women (2).
Techniques of Magnetic resonance imaging (MRI) such as
dynamic contrast-enhanced MRI (DCE MRI) and diffusion-
weighted (DW) techniques are among those of interest, as they
allow noninvasive digital biomarker measurements of tissue
properties that are highly valuable for assessment of tumor
progression (3).
Dynamic contrast-enhanced MRI (DCE MRI) sensitivity
in diagnosis of breast cancer is relatively high ranging from
88% to 100% for invasive breast malignancies (4,5).
However the reported speciﬁcity of DCE MR imaging has
been largely variable, ranging from 37% to 97% (6).
DCE MRI speciﬁcity is variable depending on lesion crite-
ria that used in differentiation between benign and malignant
breast tumors (7).
The commonly used lesion criteria used for characterization
of breast lesions by DCE MRI are lesions morphology and
enhancement kinetics (8,9).
According to BIRAD MRI lexicon, morphological evalua-
tion of breast lesions is done by evaluating its shape, margins,
and enhancement characteristics, enhancement distribution,
and internal enhancement pattern. Kinetic evaluation is done
by detecting the initial and post-initial enhancement of the
breast lesion (10).
In order to increase breast MRI speciﬁcity, diffusion-
weighted imaging (DWI) was designed (10).
Diffusion-weighted imaging (DWI) is a noninvasive tech-
nique which measures the free water protons random motion
and evaluates the exchange (diffusion) of water molecules
among compartments of breast tissues. Rate of diffusion is
varying between pathologic and nonpathologic breast tissues
(11).
The quantitative value of water molecules diffusion
between tissue components is expressed by apparent diffusion
coefﬁcient (ADC) value. This value is proved to be different
between benign and malignant breast lesions (11).
From 2002, a lot of studies (12–19) have revealed the use-
fulness of breast DWI in differentiation of benign from malig-
nant lesions of the breast. These studies proved that the
sensitivity of breast DWI was in the range of 80–96% and
its speciﬁcity was in the range of 46–91%. Yabuuchi et al.
(20) concluded 92% sensitivity and 86% speciﬁcity and also
Partridge et al. (21) concluded that there is 10% improvement
in the PPV when combining DWI with dynamic contrast-
enhanced MRI (DCE-MRI) in the differentiation of breast
masses (7,8).2. Patients and methods
2.1. Patients
This prospective study was carried out in the period between
January 2011 and January 2015 in diagnostic radiology
department of Mansoura University Hospitals. The study
comprised 71 women (age range, 28–75 years; mean age
46.6 years) with 74 suspicious breast lesions based on physical
examination, mammography and ultra-sonography.
2.1.1. Inclusion criteria
1. Patient with suspicious breast lesion at mammography or
breast ultrasound or with suspicious clinical ﬁndings.
2. Patients who are suspected to have local regional recur-
rence after resection of malignant breast lesion.
3. Patients who are suspected to have tumor residual follow-
ing chemotherapy or radiotherapy sessions.
2.1.2. Exclusion criteria
1. Patients with history of breast biopsy within 1 month.
2. Patients without a detectable lesion on MRI corresponding
to clinically or mammographically deﬁned lesion.
3. Patients without histopathologic conﬁrmation of the lesion.
4. Contraindication to perform MRI examination (cardiac
pacemaker, or metallic aneurysm clips).
All the patients underwent full history taking, general and
local examination. All patients underwent diffusion weighted
MRI and dynamic contrast enhanced MRI examination and
the results of breast MRI were compared with the histo-
pathological results that were used as the standard diagnostic
method.
2.2. MR imaging protocol
All patients were examined using a 1.5-T magnetic resonance
machine. All patients were examined in the prone position
using dedicated breast coil. MR Imaging was done within
7–14 days of menstrual cycle in premenopausal women.
Examination included image acquisition followed by image
post-processing.
2.3. Image acquisition
The conventional MRI protocol included Localizing sagittal
view (scout view), axial nonfat saturated T1WI obtained by
FSE with the following imaging parameters: TR 450 ms, TE
Diffusion and contrast enhanced MRI in breast tumors 79314 ms, slice thickness 3 mm, ﬁeld of view (FOV) 300–360 mm
and matrix was 307 · 512, and Short TI inversion recovery
(STIR) with the following parameters: TR 7000–9000 ms, TE
70 ms and inversion time (TI) was 150 ms, slice thickness
was 3–4 mm with inter slice gap 1 mm, ﬁeld of view (FOV)
300–360 mm and the matrix was 307 · 512. Dynamic contrast
enhanced MRI was made in the axial plane with fat suppres-
sion by applying fat saturated pulse. The sequence used was
FLASH 3 D GRE-T1W1 with the following parameters: TR
4–8 ms, TE 2 ms, ﬂip angle 20–25, slice thickness 2 mm with
no inter-slice gap, ﬁeld of view (FOV) 300–360 mm and the
matrix was 307 · 512. Dynamic contrast enhanced MRI was
performed after injection of a bolus of gadopentetate dimeglu-
mine, in a dose of 0.1 mmol/kg using an automated injector at
a rate of 3–5 ml/s through a 18–20 gauge intravenous cannula
inserted in an antecubital vein. Contrast injection was followed
by a bolus injection of saline (total of 20 ml at 3–5 ml/s).
Dynamic study consists of one precontrast and 5 postcontrast
series, each of them took about 1.16 min with a break between
the precontrast and postcontrast study about 20 s.
Diffusion-weighted images were obtained before dynamic
images using a diffusion-weighted echo-planar imaging (EPI)
sequence with parallel imaging. Sensitizing diffusion gradients
in three orthogonal directions with b values of 0, 500, and
1000 s/mm2 were applied. The ADC maps were created auto-
matically and the ADC values were calculated.
2.4. Image post-processing
Image postprocessing includes Image subtraction which was
obtained by subtracting each of pre-contrast images from each
post-contrast series images, Creation of time to signal intensity
curves for suspicious enhancing lesions, and maximum inten-
sity projection (MIP) views obtained through each orthogonal
plane, producing sagittal, coronal and axial projections.
2.5. MRI interpretation
STIR images were ﬁrst examined to detect the presence or
absence of any lesion or cysts. In dynamic contrast
enhanced MRI the type of lesion enhancement (mass or
non-mass-like enhancement) was determined and morpho-
logic features were analyzed. For mass enhancement lesions,
the shape, margins, signal intensity on STIR and T1
weighted images were assessed as well as enhancement char-
acteristics of the lesion. For non-mass lesions, the distribu-
tion of enhancement, internal enhancement pattern, and
symmetry were evaluated.
Evaluation of enhancement kinetics of the lesion was done
by detecting the peak percentage of signal intensity increase at
the early postcontrast phase, (wash-in rate) and the shape of
the curve after the early phase enhancement (washout kinet-
ics). A wash-in rate of >80% was deﬁned as strong enhance-
ment, between 50% and 80% as intermediate enhancement,
and <50% as slow enhancement. Types of curves were deﬁned
according to delayed-phase enhancement as persistent type I
curve (continuing steady signal intensity increase throughout
the dynamic course), plateau type II curve (signal intensity
does not change in the delayed phase), and washout type III
curve (more than 10% loss of the signal intensity over the
time).MRI BI-RADS classiﬁcation was done for each lesion
based on the combination of morphologic and kinetic criteria.
DWI was then evaluated regarding the signal intensity and
the mean ADC of each lesion was measured by placing the
ROI manually within the solid portion of the lesion.2.6. Statistical analysis
Data were tabulated, coded and then analyzed using the com-
puter program SPSS (Statistical package for social science)
version 17.0.
2.7. Descriptive data
Descriptive statistics were calculated in the form of
1. Mean ± Standard deviation (SD).
2. Median and range (Minimum – maximum).
3. Frequency (Number-percent).
2.8. Analytical statistics
In the statistical comparison between the different groups, the
signiﬁcance of difference was tested using one of the following
tests:
1. Student’s t-test used to compare between mean of two
groups of numerical (parametric) data.
2. Mann–Whitney U-test used to compare between mean of
two groups of numerical (non-parametric) data.
3. Inter-group comparison of categorical data was performed
by using chi square test (X2-value).
The sensitivity, speciﬁcity, positive predictive value, nega-
tive predictive value and accuracy were calculated for dynamic
MRI and DWI. Also ADC was examined at different cutoff
points using ROC curve analysis to determine the best cutoff
point as well as the diagnostic power of each test.
A P value <0.05 was considered statistically signiﬁcant.3. Results
All 71 patients compromised in this study underwent both
DCE-MRI and DWI for their suspicious breast lesions and
they had a histopathologic reference standard test for their
index lesion. Histopathologic analysis revealed benign lesion
in 38 patients (51.35%) and malignant lesion in 36 patients
(48.65%).
The histopathologic types of 38 benign lesions were as fol-
low (Table 1): 14 lesions (36.8%) were ﬁbroadenomas
(Figs. 3 and 4), 6 lesions (15.8%) were ﬁbrocystic changes
(FCC) (Fig. 5), 5 lesions (13.2%) were mastitis (3 acute infec-
tious mastitis and 2 chronic granulomatous mastitis), 5 lesions
(13.2%) were fat necrosis, 4 lesions (10.5%) were postopera-
tive scar, and 4 lesions (10.5%) were postoperative seroma.
The histopathologic types of 36 malignant lesions were as
follows (Table 2): 20 lesions (55.6%) were invasive duct carci-
noma (Fig. 7), 6 lesions (16.7%) were invasive lobular carci-
noma, 3 lesions (8.3%) were mucinous carcinoma (Fig. 6), 3
Table 1 Histopathological diagnoses of 38 benign breast
lesions.
Histopathological type of benign breast lesions No %
Fibroadenoma 14 36.8
Fibro cystic change (disease) 6 15.8
Mastitis 5 13.2
Fat necrosis 5 13.2
Postoperative scar 4 10.5
Postoperative seroma 4 10.5
Total 38
Table 2 Histopathological diagnoses of 36 malignant breast
lesions.
Histopathological type of malignant breast lesions No %
Invasive duct carcinoma 20 55.6
Invasive lobular carcinoma 6 16.7
Mucinous carcinoma 3 8.3








Side RT No 21 20 0.98
% 55.3% 55.6%
LT No 17 16
% 44.7% 44.4%
Site Upper outer quadrant No 15 20 0.7
% 39.5% 55.6%
Upper inner quadrant No 7 6
% 18.4% 16.7%
Lower outer quadrant No 8 5
% 21.1% 13.9%
Lower inner quadrant No 6 4
% 15.8% 11.1%
Retroareolar No 2 1
% 5.3% 2.8%
P: Probability.
Test used: chi-square test.
Table 4 Comparison between histopathological results as
regards size of lesions.
Benign Malignant P
Size (cm) Median 2.8 3.0 0.47
Range 1.0–7.0 1.5–6.5
P: Probability.
Test used: Mann–Whitney U test.
Table 5 Shows the morphologic characteristics of breast
lesions (as regards the shape and margin) in correlation with
histopathological results.
Benign Malignant P
Shape Rounded No 7 0 <0.0001
% 18.4% 0.0%
Ovoid No 10 0
% 26.3% 0.0%
Lobulated No 5 9
% 13.2% 25.0%
Irregular No 16 27
% 42.1% 75.0%
Margin Smooth No 22 0 <0.0001
% 57.9% 0.0%
Irregular No 8 20
% 21.1% 55.6%
Speculated No 8 16
% 21.1% 44.4%
P: Probability.
Test used: chi-square test.
794 M.A.H. El Bakry et al.lesions (8.3%) were medullary carcinoma, 3 lesions (8.3%)
were ductal carcinoma in situ (DCI) (Fig. 8), and 1 lesion
(2.8%) was metastasis from squamous cell carcinoma of the
right cheek.
According to the side of the lesions there were 21 benign
lesions and 20 malignant lesions on the right breast and 17
benign lesions and 16 malignant lesions on left breast (Table 3).
According to the site of breast lesions, there were 35 lesions
in the upper outer quadrant (15 were benign lesions and 20
were malignant lesions), 13 lesions in upper inner quadrant
(7 were benign lesions and 6 were malignant lesions), 13 lesionsin lower outer quadrant (8 were benign lesions and 5 were
malignant lesions), 10 lesions in lower inner quadrant (6 were
benign lesions and 4 were malignant lesions), and 3 lesions in
retroareolar region (2 were benign lesions and 1 was malignant
lesion) (Table 3).
The average size of the benign lesions was 2.8 cm with
range 1–7 cm and the average size of malignant lesions was
3 cm with range 1.5–6.5 cm (Table 4).
According to the shape of the lesions there were 7 rounded
lesions all of them were benign 10 ovoid lesions: all of them
were benign 14 lobulated lesions: 5 of them were benign and
9 were malignant; and 43 irregular lesion: 16 of them were
benign and 27 were malignant (Table 5).
According to the margins of the lesions there were 22
smooth margin lesions: all of them were benign; 28 irregular
margin lesions: 8 of them were benign and 20 were malignant;
and 24 speculated margin lesion: 8 of them were benign and 16
were malignant (Table 5).
According to contrast enhancement pattern of the lesions
homogenous enhancement was noted in 20 lesions: 14 lesions
were benign and 6 lesions were malignant; heterogeneous
enhancement was noted in 35 lesions: 8 lesions were benign
and 27 lesions were malignant; rim enhancement was noted
in 16 lesions: all of them were benign; and nonmass enhance-
ment was noted in 3 lesions: all of them were malignant
(Table 6).
According to the enhancement kinetics wash in rate was
slow (<50%) in 16 lesions: all of them were benign; interme-
diate wash in rate (50–80%) in 22 lesions: 20 lesion were
Table 6 Shows the enhancement pattern and enhancement kinetics (as regards wash in rate and shape of time/signal intensity curve)
of breast lesions in correlation with histopathological results.
Groups P
Benign Malignant
No % No %
Enhancement pattern Homogenous enhancement 14 36.8 6 16.7 <0.0001
Heterogeneous enhancement 8 21.1 27 75.0
Rim enhancement 16 42.1 0 0.0
Nonmass enhancement 0 0.0 3 8.3
Wash in rate Slow enhancement (<50%) 16 42.1 0 0.0 <0.0001
Intermediate enhancement (50–80%) 20 52.6 2 5.6
Strong enhancement (>80%) 2 5.3 34 94.4
Shape of time/SI curve Persistent type I 34 89.5 5 13.9 <0.0001
Plateau type II 3 7.9 9 25.0
Washout type III 1 2.6 22 61.1
P: Probability.
Test used: chi-square test.
Fig. 1 Chart shows comparison between apparent diffusion
coefﬁcient (ADC) values of 38 benign and 36 malignant breast
lesions. Median ADCs of benign and malignant breast lesions
were 2.05 and 0.92 · 10–3 mm2/s, respectively.




ADC Median 2.05 .92 <0.0001
Range .89–3.56 .68–1.85
P: Probability.
Test used: Mann–Whitney U test.
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(>80%) in 36 lesions: 2 lesions were benign and 34 lesions
were malignant (Table 6).
According to shape of dynamic curve (time/signal intensity
curve) type I (persistent curve) was noted in 39 lesions: 34
lesions were benign and 5 lesions were malignant; type II (pla-
teau curve) noted in 12 lesions: 3 lesions were benign and 9
lesions were malignant; and type III (washout curve) noted
in 23 lesions: 1 lesion was benign and 22 lesions were malig-
nant (Table 6).
By comparing the DCE-MRI ﬁndings with histopathologi-
cal ﬁndings there were 33 true-malignant lesions (BI-RADS 4
in 16 and BI-RADS 5 in 17), 32 true-benign lesions (BI-RADS
2 in 12 and BI-RADS 3 in 20), 6 misclassiﬁed benign lesions
(misclassiﬁed as BI-RADS 4), and 3 misclassiﬁed malignant
lesions (misclassiﬁed as BI-RADS 3).
DCE-MRI proved to have a sensitivity of 91.7%, a speci-
ﬁcity of 84.2%, PPV of 84.6%, NPV of 91.4% and accuracy
of 87.9% (Table 8).
In all 74 lesions, we could localize and measure the ADC
value of each lesion. The median ADC of benign lesions was
2.05 · 103 mm2/s (range 0.89–3.56 · 103) and that of malig-
nant lesions was 0.92 · 103 mm2/s (range, 0.68–1.85 · 103).
ADC values were signiﬁcantly lowered in malignant lesions
compared with benign lesions (p< 0.001) (Fig. 1) (Table 7).
ROC curves of the ADC values are represented in Fig. 2.
The cutoff value for ADC derived from the ROC analysis
was 1.32 · 103 mm2/s.
By comparing the diffusion weighted MRI ﬁndings with
histopathological ﬁndings there were 34 true-malignant
lesions, 35 true-benign lesions, 3 misclassiﬁed benign lesions,
and 2 misclassiﬁed malignant lesions.
By comparing the combined results of both DCE-MRI and
diffusion weighted MRI with histopathological ﬁndings there
were 35 true-malignant lesions, 36 true-benign lesions, 2 mis-
classiﬁed benign lesions, and 1 misclassiﬁed malignant lesion.
The combined MRI protocol of DCEMRI and DWI
proved to have a sensitivity of 97.2%, a speciﬁcity of 94.7%,
PPV of 94.6%, NPV of 97.3% and accuracy of 95.9%
(Table 8).4. Discussion
This study included 71 patients with their age ranging from 28
to 75 years and mean age of 44.71 and 48.67 years for benign
and malignant lesions respectively.
Fig. 2 Shows receiver operating characteristic (ROC) curve for
apparent diffusion coefﬁcient (ADC) values. Area under curve,
which represents probability of lesion, will be classiﬁed accurately
as benign or malignant according to ADC value, which is 0.97.
Upper left point on curve is cutoff value of ADC which is
1.32 · 103 mm2/s.
796 M.A.H. El Bakry et al.This is matched with the studies of Kriege et al., Warner
et al., and Leach et al., as all had a mean age between 40
and 50 years (22–24).
The number of lesions included in this study was 74 lesions.
Histopathologic analysis of these lesions revealed 38 benign
lesions (51.35%) and 36 malignant lesions (48.65%).
In this study, the most common site for breast lesions was
the upper outer quadrant 35 lesions (47.3%) followed by the
upper inner and lower outer quadrants each has the same num-
ber of lesions (13 lesions in each) (17.6%). The 35 lesions in the
upper outer quadrant included 15 benign and 20 malignant
lesions, denoting that both benign and malignant lesions occur
more frequently at this site.
This matches with Mahoney, and Darbre, who stated that
the most common location of both benign and malignant
lesions is in the upper outer quadrant. This may be due to
the large amount of glandular tissue located in this region
(25,26).
In this study, the two most common benign lesions were
ﬁbroadenoma and ﬁbrocystic changes which represented
36.8% and 15.8% of benign lesions respectively while the
two most common malignant lesions were invasive ductal car-
cinoma and invasive lobular carcinoma which represented
55.6% and 16.7% of malignant lesions respectively.
This matched with Li et al. who showed in their breast
lesions survey that invasive ductal carcinoma accounts for
56%, ﬁbroadenoma 20% and invasive lobular carcinoma
10% only (27).
In this study the most common shape of benign lesions was
regular shape either ovoid or rounded shapes they represents
26.3% and 18.4% of benign lesions respectively while theshape of all malignant lesions was irregular or lobulated with
high incidence for irregular shaped lesions 75% of all malig-
nant lesions included in this study.
These results matched with Wedega¨rtner et al. and Tozaki
et al. who showed that most benign lesions had ovoid or
rounded shape while malignant lesions had irregular shape
(28,29).
In this study the margins of benign lesions were variable
with predominance of smooth margins (57.9%) of all benign
lesions while the margins of malignant lesions were irregular
or speculated and they represent 55.6% and 44.4% of all
malignant lesions respectively.
These results matched with Mahoney et al. who reported
that most of benign lesions showed smooth margins while
malignant lesion showed irregular or speculated margins (30).
In this study according to enhancement pattern, homoge-
nous enhancement was seen in 36.8% of benign lesions and
16.7% of malignant lesions, heterogeneous enhancement was
seen in 21.1% of benign lesions and 75% of malignant lesions,
rim enhancement was seen in 42.1% of benign lesions and
none of malignant lesions and ﬁnally nonmass enhancement
were seen in 8.3% of malignant lesions and none of benign
lesions.
Morris, concluded that homogeneous enhancement is sug-
gestive of a benign process; however, in small lesions, one must
be careful as spatial resolution may limit evaluation. Also he
concluded that the most frequent enhancement pattern among
the malignant lesions was heterogeneous enhancement (96%)
(31).
In this study wash in rate was slow (<50%) in 42.1% of
benign lesions and none of malignant lesions, intermediate
(50–80%) in 52.6% of benign lesions and 5.6% of malignant
lesions, strong (>80%) in 5.3% of benign lesions and 94.4%
of malignant lesions.
These results also matched with Kuhl et al. and Malich
et al. who concluded that malignant lesions tend to exhibit
strong and fast enhancement >80% in the ﬁrst 2 min after
contrast injection (32,33).
Also these results matched with Kul et al. who showed that
95.7% of the malignant lesions revealed strong early enhance-
ment (10).
In this study, according to shape of time/signal intensity
curve, type I persistent curve was seen in 89.5% of benign
lesions and 13.9% of malignant lesions, type II plateau curve
was seen in 7.9% of benign lesions and 25% of malignant
lesions, and type III washout curve was seen in 2.6% of benign
lesions and 61.1% of malignant lesions.
These results matched with Kul et al. who showed that type
I persistent curve was seen in 81.1% of benign lesions and
12.8% of malignant lesions, type II plateau curve was seen
in 10.8% of benign lesions and 40.4% of malignant lesions,
and type III washout curve was seen in 8.1% of benign lesions
and 44.7% of malignant lesions (10).
In this study, the sensitivity and speciﬁcity of DCE-MRI
examination were 91.7% and 84.2% respectively; this was
based on the combination of morphologic and kinetic criteria.
These results disagree with Kul et al. who reported higher
sensitivity (97.9%) and lower speciﬁcity (75.7%) than our
study (10).
Our results also disagree with Hetta, and he proved that the
sensitivity and speciﬁcity of DCE-MRI examination were 80%
and 73.33% respectively (11).
(A) (B)
(C)
Fig. 3 Right breast ﬁbroadenoma in 38-year-old woman. (A) dynamic contrast-enhanced subtracted image shows smooth marginated,
round shaped mass with nonenhancing internal septation (arrow) in lower outer quadrant of right breast. (B) Time–signal intensity curve
of mass shows type I persistent curve. (C) Apparent diffusion coefﬁcient (ADC) map reveals increased diffusion (ADC= 2.16 · 10–3
mm2/s) within mass. Mass was correctly classiﬁed as benign (BIRAD 3) according to combined imaging protocol.
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(A) (B)
(C)
Fig. 4 Left breast ﬁbroadenoma in 50-year-old woman. (A) dynamic contrast-enhanced subtracted image shows well-marginated, ovoid-
shaped mass with nonenhancing internal septation (arrow) in lower outer quadrant of left breast. (B) Time–signal intensity curve of mass
shows type I persistent curve. (C) Apparent diffusion coefﬁcient (ADC) map reveals increased diffusion (ADC= 1.6 · 10–3 mm2/s) within
mass. Mass was correctly classiﬁed as benign (BIRAD 3) according to combined imaging protocol.
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(A) (B)
(C)
Fig. 5 Bilateral ﬁbrocystic changes (FCC) in 48-year-old woman. (A) dynamic contrast-enhanced subtracted image shows bilateral
well-marginated, ovoid-shaped cystic lesions with rim enhancement (arrows). (B) Time–signal intensity curve of the enhancing rim
of the right sided lesion shows type I persistent curve. (C) Apparent diffusion coefﬁcient (ADC) map reveals increased diffusion
(ADC= 2.7–3.7 · 10–3 mm2/s) within right and left cysts respectively. Cysts were correctly classiﬁed as benign (BIRAD 2) according to
combined imaging protocol.
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(A) (B)
(C)
Fig. 6 Left breast grade II invasive lobular carcinoma in 70-year-old woman. (A) dynamic contrast-enhanced subtracted image shows
irregular mass with speculated margins seen at the upper outer quadrant of left breast. (B) Time–signal intensity curve of mass shows type
III washout curve. (C) Apparent diffusion coefﬁcient (ADC) map reveals restricted diffusion (ADC= 0.88 · 10–3 mm2/s) within mass.
Mass was correctly classiﬁed as malignant (BIRAD 4b) according to combined imaging protocol.
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(A) (B)
(C)
Fig. 7 Left breast grade II invasive duct carcinoma in 48-year-old woman. (A) dynamic contrast-enhanced subtracted image shows
irregular mass with speculated margins seen at the lower outer quadrant of left breast. (B) Time–signal intensity curve of mass shows type
III washout curve. (C) Apparent diffusion coefﬁcient (ADC) map reveals restricted diffusion (ADC= 0.85 · 10–3 mm2/s) within mass.
Mass was correctly classiﬁed as malignant (BIRAD 4b) according to combined imaging protocol.
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(C)
Fig. 8 Right breast grade II invasive duct carcinoma in 60-year-old woman. (A) Dynamic contrast-enhanced subtracted image shows
irregular area of clumped non-mass-like enhancement on the lower inner quadrant of right breast. (B) Time–signal intensity curve of mass
shows type III washout curve. (C) Apparent diffusion coefﬁcient (ADC) map reveals restricted diffusion (ADC= 0.89 · 10–3 mm2/s)
within mass. Mass was correctly classiﬁed as malignant (BIRAD 4b) according to combined imaging protocol.
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Table 8 Sensitivity and speciﬁcity of dynamic contrast-
enhanced MRI (DCE-MRI), diffusion-weighted imaging
(DWI), and combined MRI in 36 malignant and 38 benign
breast lesions.
Results DCE-MRI DWI Combined
Sensitivity (%) 91.7 94.4 97.2
Speciﬁcity (%) 84.2 92.1 94.7
PPV (%) 84.6 91.9 94.6
NPV (%) 91.4 94.6 97.3
Accuracy 87.9 93.2 95.9
Diffusion and contrast enhanced MRI in breast tumors 803In an attempt to increase the diagnostic efﬁcacy of breast
MRI, we evaluated the additional role of DWI.
In this study according to the lesion signal in diffusion
weighted image, free diffusion showed 92.1% of benign lesions
and 5.6% of malignant lesions, while restricted diffusion
showed 7.9% of benign lesions and 94.4% of malignant
lesions.
Kul et al., revealed the effectiveness of DWI for differenti-
ating malignant from benign breast tumors. Consistent with
this study, malignant lesions revealed signiﬁcantly lower
ADC values than benign lesions (10).
In this study the median ADC value of benign lesions was
2.05 · 103 mm2/s (range 0.89–3.56 · 103 mm2/s), and med-
ian ADC value of malignant lesions was 0.92 · 103 mm2/s
(range 0.68–1.853 · 103 mm2/s).
These results disagree with Kul et al. who reported that the
median ADC values of malignant and benign lesions were 0.75
and 1.26 · 103 mm2/s, respectively (10).
This study showed that the best ADC cutoff value to differ-
entiate between benign and malignant lesions was
1.32 · 103 mm2/s. Malignant lesions exhibited lower mean
ADC values compared with those of benign lesions.
These results match with Yabuuchi et al. who demonstrated
an ADC value less than 1.3 · 103 mm2/s as the strongest indi-
cator of malignancy (20).
These results were compared with Hetta and he showed
that the best ADC cutoff value to differentiate between benign
and malignant lesions was 1.2 · 103 mm2/s (11).
Palle and Reddy found that the ADC value obtained with
low b-values (0 and 150 s/mm2) is higher than that obtained
with higher b-values (499 and 1500 s/mm2) for all lesion types
due to contribution of main perfusion effects to the ADC. So,
they calculated the ADC with high b-values (800) to avoid the
signal attenuation caused by perfusion effects at low b-values
(34).
This study, reported that DWI has higher sensitivity and
speciﬁcity than those of DCE-MRI in the characterization of
breast lesion enhancement. The sensitivity and speciﬁcity of
breast MR diffusion were 94.4% and 92.1% respectively.
Our results were lower than Abdulghaffar and Tag-Aldeen
as they showed that sensitivity and speciﬁcity of breast MR
diffusion were 95.4% and 97.5%, respectively (35).
Also our results were higher than Kul et al. and they pro-
vided 91.5% sensitivity and 86.5% speciﬁcity for breast MRI
diffusion (10).
In this study the combined DCE-MRI and DWI protocols,
provided 97.2% sensitivity and 94.7% speciﬁcity in the diagno-
sis of breast cancer.These results are higher than the results obtained by Kul
et al. who provided 95.7% sensitivity and 89.2% speciﬁcity
for combined DCE-MRI and DWI protocols (10).
So our study proved that the addition of DWI to DCE-
MRI improved the sensitivity and speciﬁcity of dynamic con-
trast enhanced breast MRI by 5.5% and 10.5% respectively.5. Conﬂict of Interest
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